Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
4.640
+0.110 (2.43%)
At close: Aug 20, 2025, 4:00 PM
4.640
0.00 (0.00%)
After-hours: Aug 20, 2025, 4:00 PM EDT
Personalis Employees
As of December 31, 2024, Personalis had 229 total employees, including 228 full-time and 1 part-time employees. The number of employees increased by 4 or 1.78% compared to the previous year.
Employees
229
Change (1Y)
4
Growth (1Y)
1.78%
Revenue / Employee
$350,729
Profits / Employee
-$398,777
Market Cap
411.90M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 229 | 4 | 1.78% |
Dec 31, 2023 | 225 | -174 | -43.61% |
Dec 31, 2022 | 399 | 73 | 22.39% |
Dec 31, 2021 | 326 | 91 | 38.72% |
Dec 31, 2020 | 235 | 53 | 29.12% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PSNL News
- 14 days ago - Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
- 14 days ago - Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Personalis Reports Second Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - Personalis to Announce Second Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients - Business Wire
- 2 months ago - Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO - Business Wire
- 2 months ago - New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse - Business Wire